Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.
The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.
Details
News Market Reaction – COCP
On Sep 3, the day this news came out, COCP closed 2.64% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time.
Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. The Cocrystal Pharma presentation is posted to the Company website here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.